Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Bicycle Therapeutics Plc ADR (BCYC)
Bicycle Therapeutics Plc ADR (BCYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 740,259
  • Shares Outstanding, K 30,043
  • Annual Sales, $ 14,460 K
  • Annual Income, $ -112,720 K
  • 60-Month Beta 0.80
  • Price/Sales 26.71
  • Price/Cash Flow N/A
  • Price/Book 1.94
Trade BCYC with:

Options Overview Details

View History
  • Implied Volatility 87.33% ( -0.76%)
  • Historical Volatility 64.56%
  • IV Percentile 72%
  • IV Rank 30.19%
  • IV High 174.99% on 11/16/23
  • IV Low 49.41% on 09/22/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 126
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 1,701
  • Open Int (30-Day) 1,429

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.23
  • Number of Estimates 5
  • High Estimate -1.11
  • Low Estimate -1.36
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +5.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.48 +49.51%
on 02/05/24
24.85 -0.85%
on 02/23/24
+6.92 (+39.05%)
since 01/23/24
3-Month
13.31 +85.12%
on 11/27/23
24.85 -0.85%
on 02/23/24
+10.82 (+78.29%)
since 11/22/23
52-Week
12.54 +96.49%
on 11/13/23
28.91 -14.77%
on 06/20/23
+1.24 (+5.30%)
since 02/23/23

Most Recent Stories

More News
Why Shares of Bicycle Therapeutics Were Rising on Monday

The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.

NVS : 103.90 (+1.07%)
BCYC : 24.64 (+2.75%)
Why Bicycle Therapeutics Stock Raced Ahead Today

The company's latest attempt at capital raising seems to be having enviable success.

GS : 391.05 (+0.15%)
JEF : 42.08 (+1.45%)
BCYC : 24.64 (+2.75%)
3 Biotech Stocks Losing Market Value

There is a growing demand for healthcare solutions, and the biotech industry will likely benefit from it. However, not all biotech stocks are well-positioned to capitalize on the industry tailwinds. Therefore,...

BCYC : 24.64 (+2.75%)
CRMD : 3.28 (+1.23%)
XXII : 0.1390 (-7.33%)
Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet

The consensus price target hints at a 146.3% upside potential for Bicycle Therapeutics PLC Sponsored ADR (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward...

BCYC : 24.64 (+2.75%)
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 24.64 (+2.75%)
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 24.64 (+2.75%)
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 24.64 (+2.75%)
Bicycle Therapeutics Enhances Leadership Team with Key Appointments

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 24.64 (+2.75%)
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates

Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.

NVS : 103.90 (+1.07%)
APTX : 0.0960 (+3.11%)
BCYC : 24.64 (+2.75%)
ANVS : 9.94 (-4.05%)
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 24.64 (+2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 26.51
2nd Resistance Point 25.68
1st Resistance Point 25.16
Last Price 24.64
1st Support Level 23.81
2nd Support Level 22.98
3rd Support Level 22.46

See More

52-Week High 28.91
Last Price 24.64
Fibonacci 61.8% 22.66
Fibonacci 50% 20.73
Fibonacci 38.2% 18.79
52-Week Low 12.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar